[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"persistent-atrial-fibrillation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:persistent-atrial-fibrillation":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,47,0,25,[9,47,78,101,132,152,175,207,227,254,274,297,310,333,354,377,401,428,452,484,512,538,560,589,610],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053980","comprehensive-left-atrial-appendage-occlusion-with-rhythm-restoration-100053980",false,"NCT07523620","Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration","CLEAR","Inclusion Criteria:\n\n* Subject must provide written informed consent prior to any clinical investigation-related procedure.\n* 18 years of age or older, or the age of legal consent\n* CHA2DS2-VASc score of ≥ 3 for women and ≥ 2 for men\n* Able to stop anticoagulation by 90 days post index procedure\n* Able to adhere to the protocol defined post-concomitant procedure pharmacologic regimen of OAC for at least 60 days followed by SAPT\n* Plans to undergo a catheter ablation procedure including PVI due to symptomatic, recurrent, drug-refractory PAF or PersAF\n* Documented symptomatic PAF or PersAF. Documentation requirements are as follows:\n\nParoxysmal:\n\n* Physician's note indicating recurrent self-terminating AF with ≥ 2 episodes of PAF within the 12 months prior to enrollment AND\n* One electrocardiographically documented PAF episode within 12 months prior to enrollment.\n\nPersistent: Continuous AF sustained beyond 7 days and less than 1 year that is documented by\n\n* Physician's note, AND either\n* 24-hour Holter within 180 days prior to enrollment, showing continuous AF, OR\n* Two electrocardiograms (from any form of rhythm monitoring) showing continuous AF:\n\n  * That are taken at least 7 days apart but less than 12 months apart\n  * If electrograms are more than 12 months apart, there must be one or more Sinus Rhythm recordings in between or within 12 months prior to consent\u002Fenrollment\n  * The most recent electrocardiogram must be within 180 days of enrollment.\n\nNOTE: Documented evidence of the AF episode must either be continuous AF on a 12-lead ECG or include at least 30 seconds of continuous AF from another ECG device.\n\nExclusion Criteria:\n\n* Known contraindication or allergy to NOACs or aspirin, preventing use of the drugs post-procedure\n* Required to take P2Y12 platelet inhibitor after the study procedure (e.g., due to percutaneous coronary intervention)\n* Patients with heart prosthetic valves\n* Patient implanted with an inferior vena cava filter\n* Patients with left ventricular ejection fraction ≤30%\n* Patients with NYHA Class IV heart failure\n* Patients who have undergone any invasive intervention or surgery within 30 days prior to the index procedure (diagnostic catheterization is not within scope, however, percutaneous coronary intervention is within scope)\n* Patients who have experienced stroke or transient ischemic attack within 90 days prior to study procedure\n* Patients who have had previous attempt at LAA surgical or epicardial intervention (e.g., stapling, suturing, ligation, epicardial LAA management device)\n* Patients previously diagnosed long-standing persistent atrial fibrillation (Continuous AF greater than 1 year in duration)\n* Patients with arrhythmia due to reversible causes including thyroid disorders, acute alcohol intoxication, electrolyte imbalance, severe untreated sleep apnea, and other major surgical procedures within 90 days prior to the study procedure\n* Patients unable to receive heparin or an acceptable alternative to achieve adequate intra-procedural anticoagulation\n* Patients with a stent, constriction, or stenosis in a pulmonary vein\n* Patients with severe mitral regurgitation (regurgitant volume ≥ 60 mL\u002Fbeat, regurgitant fraction ≥ 50%, and\u002For effective regurgitant orifice area ≥ 0.40cm2)\n* Patients with severe renal failure (estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73m2) or on chronic dialysis\n* Patients with severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms\n* Patients with hypertrophic cardiomyopathy (maximal LV wall thickness ≥ 15 mm in the absence of abnormal loading conditions such as hypertension or aortic stenosis)","ALL","18 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of this clinical investigation is to evaluate the feasibility, safety, and effectiveness of a concomitant procedure involving the Volt PFA System and Amulet 2 device in patients indicated for both AF ablation and percutaneous LAAO.",[27,28,29],"Atrial Fibrillation (AF)","Paroxysmal AF","Persistent Atrial Fibrillation",[31,32,33,29],"Left Atrial Appendage","Atrial Fibrillation","Paroxysmal Atrial Fibrillation","RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":38},"2026-03-31",{"date":42,"type":21},"2028-02-28",{"name":44,"class":45},"Abbott Medical Devices","INDUSTRY",16,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100644942","atrial-remodeling-after-pfa-substrate-modification-for-persistent-af-peaf-100644942","NCT07675395","Atrial Remodeling After PFA Substrate Modification for Persistent AF (PeAF)","Pulsed-Field Ablation for Persistent Atrial Fibrillation: Impact of Atrial Remodeling After Substrate Modification","Inclusion Criteria:\n\n* Diagnosis of persistent atrial fibrillation\n* Left atrial anteroposterior (AP) diameter greater than 4 cm and less than 6 cm\n* Anti-arrhythmic medications (except amiodarone) discontinued for at least 5 half-lives before the procedure\n* No use of beta-blockers or diuretics before or after the ablation procedure\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Paroxysmal atrial fibrillation\n* Previous left atrial surgery or catheter ablation procedure, including left atrial appendage closure\n* Atrial fibrillation due to reversible causes, such as thyroid disorders, acute alcohol intoxication, or other major surgeries within the 90 days preceding the procedure\n* Myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, or coronary artery bypass grafting within 90 days of the procedure\n* Known presence of cardiac thrombus\n* Stroke or transient ischemic attack within the last 90 days\n* Any other anatomical or comorbid condition that, in the investigator's opinion, could limit the patient's ability to participate in the clinical trial, comply with follow-up requirements, or impact the scientific validity of the clinical trial results",{"count":55,"type":21},30,[24],"Atrial fibrillation (AF) is associated with both electrical and structural remodeling of the left atrium. While successful catheter ablation has been shown to reverse some aspects of atrial remodeling, the impact of pulsed-field ablation (PFA) - a non-thermal ablation technology that selectively targets cardiomyocytes while sparing surrounding structures - on atrial remodeling in patients with persistent AF undergoing extensive substrate modification remains unclear.\n\nThis is a prospective, single-center, single-arm observational study conducted at Taipei Veterans General Hospital. The study will enroll 30 patients with persistent atrial fibrillation who undergo pulmonary vein isolation (PVI) and extensive substrate modification using the FARAWAVE \u002F FARADRIVE Catheter and FARASTAR System.\n\nThe primary objective is to evaluate left atrial structural remodeling following PFA, including changes in LA size, atrial strain, extent of atrial fibrosis, and atrial hemodynamic function. The secondary objective is to assess AF-free survival between 3 and 12 months after the procedure, and its relationship to atrial remodeling. All participants will be followed for 12 months, with an interim analysis conducted once all subjects complete their 6-month follow-up.",[29,27,59,60],"Atrial Remodeling","Pulsed Field Ablation",[60,29,32,59,62,63,64,65],"Substrate Modification","Atrial Fibrosis","Cardiac MRI","Posterior Wall Isolation","NOT_YET_RECRUITING","2026-06-30",{"date":69,"type":38},"2026-07-02",{"date":71,"type":21},"2026-07-01",{"date":73,"type":21},"2028-12-31",{"name":75,"class":76},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",1,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100627106","evaluation-of-novel-waveforms-delivered-using-the-farapulse-pfa-system-100627106","NCT07444320","Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System","A Multicenter Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System in Patients With Atrial Fibrillation","IMPULSE-EVO","Inclusion Criteria:\n\n1. ≥ 18 years of age, or older if required by local law\n2. Persistent Atrial Fibrillation or Paroxysmal Atrial Fibrillation\n\n   1. Persistent AF Documented:\n\n      * Physician's note confirming the presence of persistent atrial fibrillation and the arrhythmia symptoms\n      * Within 180 days prior to Enrollment: A 24-hour continuous ECG recording confirming continuous AF OR Two (2) ECGs from any regulatory-cleared rhythm monitoring device showing continuous AF taken at least 7 days apart.\n\n      OR\n   2. Paroxysmal AF Documented:\n\n      * Physician's note confirming the presence of paroxysmal atrial fibrillation and the arrhythmia symptoms\n      * Within 180 days of the Enrollment Date, one (1) ECG from any regulatory-cleared rhythm monitoring device showing atrial Fibrillation (AF)\n3. Willing and capable of providing informed consent\n4. Willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical investigational center\n\nExclusion Criteria:\n\n1. Atrial exclusions - any of the following atrial conditions:\n\n   1. Left atrial anteroposterior diameter ≥ 5.5 cm, or if LA diameter is not available, LA non-indexed volume \\> 100 mL. If both values are available, only the LA diameter will be used to confirm eligibility.\n   2. Any prior atrial endocardial, epicardial, or surgical ablation procedure for arrhythmia other than ablation for right-sided SVT or cavotricuspid isthmus ablation\n   3. Any prior atrial surgery\n   4. Current atrial myxoma\n   5. Current Left Atrial Thrombus\n   6. Any PV abnormality, stenosis, or stenting (common and middle PVs are admissible)\n2. Cardiovascular Conditions - Any of the following cardiovascular conditions:\n\n   1. History of sustained ventricular tachycardia (VT) or any ventricular fibrillation (VF)\n   2. Atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible\u002Fnon-cardiac causes\n   3. Cardiac Devices and Implants:\n\n      * Current or anticipated pacemaker, implantable cardioverter-defibrillator or cardiac resynchronization therapy devices.\n      * Interatrial baffle, patent foramen ovale, or atrial septal defect closure device or patch.\n      * Any Left Atrial Appendage Closure or Occlusion Device, except a WATCHMAN™ device implanted \\> 90 days before Enrollment\n   4. Valvular Disease - Presence of any of the following:\n\n      * Any prosthetic heart valve, ring or repair\n      * Moderate to severe mitral valve stenosis\n      * More than moderate mitral regurgitation (≥ 3+)\n      * Moderate to severe aortic stenosis\n   5. Cardiomyopathy - Hypertrophic cardiomyopathy\n   6. Access Issues - Any IVC filter, known inability to obtain vascular access, or other contraindication to femoral access\n   7. Anticipated Cardiac Surgery - Awaiting cardiac transplantation or other planned cardiac surgery within the next 12 months\n3. Congenital Conditions - Any of the following congenital conditions:\n\n   a. Congenital heart disease with any clinically significant residual anatomic or conduction abnormality\n4. Baseline Conditions - Any of the following conditions at Baseline:\n\n   1. Heart failure - Heart failure associated with NYHA Class III or IV\n   2. Ejection Fraction - Most recent documented LVEF \\\u003C 40% within the previous 12 months\n   3. Obesity: Body Mass Index (BMI) \\> 45.0 kg\u002Fm\\^2\n   4. Hematologic Condition: Known coagulopathy or bleeding disorder\n   5. Anticoagulation Contraindication: Contraindication to, or unwillingness to use, systemic anticoagulation, or acceptable alternatives, pre-, intra- and post-procedure to achieve adequate anticoagulation\n   6. Pregnancy - Women who are confirmed to be pregnant or lactating at the time of the ablation procedure\n   7. Pulmonary Disease - Severe lung disease, severe pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen\n   8. Malignancy - Active malignancy (other than non-melanoma skin cancers)\n   9. Gastrointestinal - Clinically significant gastrointestinal problems involving the esophagus or stomach, including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration\n   10. Infection - Known active systemic infection\n   11. Sleep Apnea - Untreated diagnosed obstructive sleep apnea with apnea-hypopnea index classification of severe (\\> 30 events per hour) as per the guidelines\n   12. Life Expectancy - Predicted life expectancy of less than one (1) year per investigator medical judgment\n   13. Concurrent Enrollment - Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the sponsor to determine eligibility\n5. Any of the following events within 90 days of the Consent Date:\n\n   1. Coronary disease - Myocardial infarction (MI), unstable angina or coronary intervention\n   2. Pericardium - Pericarditis or symptomatic pericardial effusion\n   3. GI Bleeding - Gastrointestinal bleeding\n   4. Cardiac Surgery - Any cardiac surgery\n   5. Neurovascular Event - Stroke, TIA, or intracranial bleeding\n   6. Thromboembolism - Any active non-neurologic thrombus and\u002For thromboembolic event\n   7. Carotid Intervention - Carotid stenting or endarterectomy\n   8. Diabetes - Uncontrolled diabetes mellitus or a recorded HgbA1c \\> 8.0%\n6. Medical History - Any of the following conditions in the Medical History\n\n   1. Transplantation - Solid organ or hematologic transplant, or currently being evaluated for a transplant\n   2. Diaphragmatic Abnormality - Any prior history or current evidence of hemi-diaphragmatic paralysis or paresis\n   3. Coronary Disease - Any documented history of Prinzmetal angina or severe non-revascularizable coronary disease\n   4. Renal Disease - Renal insufficiency if an estimated glomerular filtration rate (eGFR) is \\\u003C 30 mL\u002Fmin\u002F1.73 m2, or with any history of renal dialysis or renal transplant\n   5. General Medical Conditions - Any other general health conditions that, in the investigator's medical opinion, would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.",{"count":87,"type":21},200,[24],"This is a multicenter, prospective, single-arm, feasibility study to evaluate the safety and effectiveness of the waveforms being delivered using the FARAPULSE PFA System in patients with Paroxysmal Atrial Fibrillation (PAF) and Persistent Atrial Fibrillation (PersAF).",[33,29],[60],"2026-06-26",{"date":67,"type":38},{"date":95,"type":38},"2026-02-12",{"date":97,"type":21},"2028-02",{"name":99,"class":45},"Boston Scientific Corporation",4,{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},"100572612","repeat-ablation-of-persistent-atrial-fibrillation-including-mitral-isthmus-catheter-ablation-with-the-farapulse-pulsed-field-ablation-system-100572612","NCT06735534","Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System","The ReMATCH Study is a Prospective, Single Arm, Open Label, Multi-center, Study Utilizing the FARAPULSE PFA System, Including the FARAWAVE and FARAPOINT PFA Catheters","ReMATCH","Inclusion Criteria:\n\n* ≥ 18 years of age, or older if required by local law\n* Single previous endocardial AF ablation procedure for PAF or PersAF that minimally included pulmonary vein isolation\n* Documented (physician's note) diagnosis of PersAF either prior to the subject's Index Procedure OR development of PersAF after the Index Procedure.\n* Documented evidence of symptomatic AF recurrence at least 60 days after the subject's Index Procedure, captured by any regulatory cleared rhythm monitoring device.\n\nOR\n\n* If diagnosed with PersAF prior to the Index Procedure, documented recurrence of symptomatic AF or atypical AFL at least 60 days after the Index Procedure, captured by any regulatory cleared rhythm monitoring device.\n* Willing and capable of providing informed consent\n* Willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical investigational center\n\nExclusion Criteria:\n\n1. Atrial exclusions - Any of the following atrial conditions:\n\n   a. Left atrial anteroposterior diameter ≥ 5.5 cm, or if LA diameter not available, non-indexed volume \\>100 ml (physician note or imaging) b. Current atrial myxoma c. Any PV abnormality, stenosis, or stenting (common and middle PVs are admissible) d. Current left atrial thrombus\n2. Cardiovascular exclusions - Any of the following CV conditions:\n\n   1. History of sustained ventricular tachycardia or any ventricular fibrillation\n   2. AF that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible \u002F non-cardiac causes\n   3. Current or anticipated implantable cardioverter defibrillator, cardiac resynchronization therapy devices, or implantable loop recorders, other than LUX-Dx. Patients with a pacemaker are permitted; however, pacemaker-dependent patients are excluded.\n\n      Prior interatrial baffle, atrial septal patch, atrial septal defect closure device, patent foramen ovale occluder Left atrial appendage closure devices are excluded, with the exception of WATCHMAN. WATCHMAN is excluded if implanted within 90 days of enrollment\n   4. Presence of any of the following:\n\n      • Any prosthetic heart valve, ring or repair\n\n      • Moderate to severe mitral valve stenosis\n\n      • More than moderate mitral regurgitation (\\>3+)\n      * Moderate to severe aortic stenosis\n   5. Hypertrophic cardiomyopathy\n   6. Any IVC filter, known inability to obtain vascular access or other contraindication to femoral access\n   7. Awaiting cardiac transplantation or other cardiac surgery within the next 12 months\n   8. Severe right ventricular dysfunction with documented echocardiography and\u002For hemodynamic data.\n3. Any of the following conditions at baseline:\n\n   1. Heart failure associated with NYHA Class III or IV\n   2. Documented LVEF \\\u003C 40% as documented within the previous 12 months\n   3. Uncontrolled hypertension (SBP \\> 160 mmHg or DBP \\> 95 mmHg on two (2) BP measurements at baseline assessment not attributable to white coat syndrome per Investigator opinion\n   4. Body Mass Index (BMI) \\>45.0\n   5. CHA2DS2-VASc score ≥5\n4. Any of the following events within 90 Days of the Consent Date:\n\n   1. Coronary disease: Myocardial infarction (MI), unstable or Prinzmetal angina or coronary intervention within 90 days of consent or any documented history of severe non-revascularize coronary disease\n   2. Cardiac surgery: Any cardiac surgery\n   3. Heart failure hospitalization: Heart failure hospitalization\n   4. Pericardium: Pericarditis or symptomatic pericardial effusion\n   5. GI bleeding: Gastrointestinal bleeding\n   6. Neurovascular event: Stroke, TIA, or intracranial bleeding\n   7. Thromboembolism: Any active non-neurologic thrombus and\u002For thromboembolic event\n   8. Carotid intervention: Carotid stenting or endarterectomy\n   9. Diabetes: Uncontrolled diabetes mellitus or a recorded HgbA1c \\> 8.0%\n5. Any of the following congenital conditions:\n\n   1. Congenital heart disease: Congenital heart disease with any clinically significant residual anatomic or conduction abnormality\n   2. Methemoglobinemia: History of known congenital methemoglobinemia\n   3. G6PD deficiency: History of known G6PD deficiency\n6. Any of the following conditions:\n\n   1. Transplantation: Solid organ or hematologic transplant, or currently being evaluated for a transplant\n   2. Diaphragmatic abnormality: Any prior history or current evidence of hemi-diaphragmatic paralysis or paresis.\n\n   Pulmonary: Severe lung disease, severe pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen d. Renal: Renal insufficiency if an estimated glomerular filtration rate (eGFR) is \\\u003C 30 mL \u002F min \u002F 1.73 m2, or with any history of renal dialysis or renal transplant e. Malignancy: Active malignancy (other than squamous cell carcinoma) f. Gastrointestinal: Clinically significant gastrointestinal problems involving the esophagus or stomach including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration g. Infections: Active systemic infection h. Required use of phosphodiesterase inhibitors within 24 hours of the ablation procedure i. Nitroglycerin intolerance: Known allergic drug reaction to nitroglycerin (excluding hypotension) j. Hematologic condition: Known coagulopathy or bleeding disorder (e.g. von Willebrand disease, hemophilia) k. Contraindication to anticoagulation: Contraindication to, or unwillingness to use, systemic anticoagulation, or acceptable alternatives, pre-, intra- and post-procedure to achieve adequate anticoagulation.\n\n   l. Pregnancy: Women of childbearing potential who are pregnant, lactating, not using medical birth control or who are planning to become pregnant during the anticipated study period m. General health conditions: Health conditions that, in the investigator's medical opinion, would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.\n\n   n. LUX-Dx ICM intolerance: Unwillingness to receive, or unable to tolerate, a subcutaneous, chronically inserted LUX-Dx ICM device o. Participation in another trial: Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the Sponsor to determine eligibility.\n\n   p. Life expectancy: Predicted life expectancy less than one (1) year",{"count":110,"type":21},376,[24],"The ReMATCH Study is a prospective, single arm, open label, multi-center, study utilizing the FARAPULSE PFA System, including the FARAWAVE and FARAPOINT PFA Catheters.",[29],[115,116,117,118,119,120,121,122,123,124],"Pulsed Field Ablation (PFA))","Pulmonary Vein Isolation","Recurrent Arrhythmia","cavo-tricuspid isthmus (CTI)","CTI dependent flutter","Anti Arrhythmic Drugs (AAD)","Atrial Flutter","Atrial Tachycardia","Atrial fibrillation","Electrical cardioversion",{"date":67,"type":38},{"date":127,"type":38},"2025-06-03",{"date":129,"type":21},"2028-01",{"name":99,"class":45},41,{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":100},"100555320","feasibility-study-of-the-faraflex-mapping-and-pfa-system-100555320","NCT06510556","Feasibility Study of the FARAFLEX Mapping and PFA System","Feasibility Study of the FARAFLEX Mapping and Pulsed Field Ablation (PFA) System in the Treatment of Persistent Atrial Fibrillation","ELEVATE-PF","Inclusion Criteria:\n\n1. Age ≥ 18 years of age, or older if required by local law\n2. Symptomatic, documented, Persistent AF or Paroxysmal AF\n3. Willing and capable of providing informed consent\n4. Willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical investigational center\n\nExclusion Criteria:\n\n1. Atrial exclusions - Any of the following atrial conditions:\n\n   * Left atrial anteroposterior diameter ≥ 5.5 cm, or if LA diameter not available, non indexed volume \\>100 ml (by MRI, CT or TTE report or physician note)\n   * Any prior atrial endocardial, epicardial or surgical ablation procedure for atrial arrhythmia other than ablation for right sided SVT\n   * Current atrial myxoma\n   * Any PV abnormality, stenosis, or stenting (common and middle PVs are admissible)\n   * Current left atrial thrombus\n2. Cardiovascular exclusions - Any of the following CV conditions:\n\n   * History of sustained ventricular tachycardia or any ventricular fibrillation AF that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible \u002F non-cardiac causes\n   * Current or anticipated pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy devices, interatrial baffle, closure device, patch, or patent foramen ovale occluder, LA appendage closure, device or occlusion\n   * Valvular disease that is symptomatic or is the cause of heart failure.\n   * Hypertrophic cardiomyopathy\n   * Any prosthetic heart valve, ring or repair including balloon aortic valvuloplasty\n   * Known inability to obtain vascular access or other contraindication to femoral access\n   * Rheumatic heart disease\n   * Awaiting cardiac transplantation or other cardiac surgery within the next 12 months\n   * Known allergic drug reaction to nitroglycerin1\n   * Known severe non-revascularizable coronary disease\n   * Pre-existing right coronary artery stent and left circumflex artery\n3. Any of the following conditions at baseline:\n\n   * Heart failure associated with NYHA Class IV\n   * LVEF \\\u003C 40%\n   * Uncontrolled hypertension (SBP \\> 160 mmHg or DBP \\> 95 mmHg on two (2) BP measurements at baseline assessment\n   * Severe right ventricular dysfunction with documented echocardiography and\u002For hemodynamic data.\n4. Any of the following events within 90 Days of the Consent Date:\n\n   * Myocardial infarction (MI), unstable or Prinzmetal angina or coronary intervention\n   * Any cardiac surgery\n   * Heart failure hospitalization\n   * Pericarditis or symptomatic pericardial effusion\n   * Gastrointestinal bleeding\n   * Stroke, TIA, or intracranial bleeding\n   * Any non-neurologic thromboembolic event\n   * Carotid stenting or endarterectomy\n5. Known coagulopathy disorder (e.g. von Willibrand's disease, hemophilia)\n6. Contraindication to, or unwillingness to use, systemic anticoagulation, or acceptable alternatives, pre-, intra- and post-procedure to achieve adequate anticoagulation.\n7. Women of childbearing potential who are pregnant, lactating, not using medical birth control or who are planning to become pregnant during the anticipated study period\n8. Any of the following health conditions that would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation, including but not limited to:\n\n   * Body Mass Index (BMI) \\> 42.0\n   * Solid organ or hematologic transplant, or currently being evaluated for a transplant\n   * Any prior history or current evidence of hemi-diaphragmatic paralysis or paresis\n   * Severe lung disease, severe pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen\n   * Renal insufficiency if an estimated glomerular filtration rate (eGFR) is \\\u003C 30 mL \u002F min \u002F 1.73 m2, or with any history of renal dialysis or renal transplant\n   * Active malignancy at enrollment (other than squamous cell carcinoma)\n   * Clinically significant gastrointestinal problems involving the esophagus or stomach including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration\n   * Active systemic infection\n   * Untreated diagnosed obstructive sleep apnea with apnea hypopnea index classification of severe (\\>30 pauses per hour)\n   * Required use of phosphodiesterase inhibitors within 24 hours of the ablation procedure\n\n10\\. Predicted life expectancy less than one (1) year 11. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the Sponsor to determine eligibility 12. Any of the following congenital conditions:\n\n* Congenital heart disease with any clinically significant residual anatomic or conduction abnormality\n* History of known congenital methemoglobinemia\n* History of known G6PD deficiency\n\nELEVATE-COR (additional) Eligibility Criteria:\n\nInclusion Criteria:\n\n1. Meets all inclusion criteria according to the ELEVATE-PF Protocol\n2. Planned for adjunctive CTI ablation\n3. Willing and capable of participating in all assessments and testing associated with this sub-study protocol.\n\nExclusion Criteria:\n\n1. Meets any of the exclusion criteria outlined in the ELEVATE-PF Protocol\n2. Pre-existing right coronary artery stent and\u002For left circumflex artery stent\n3. Known severe non-revascularizable coronary disease\n4. Moderate to severe coronary artery disease that in the opinion of the investigator would put the patient at increased risk\n5. Known calcium score ≥1000\n6. Renal insufficiency if an estimated glomerular filtration rate (eGFR) is \\\u003C 30 mL \u002F min \u002F 1.73 m2, or with any history of renal dialysis or renal transplant\n7. Contraindication to IVUS\n8. Body Mass Index (BMI) \\> 35.0",{"count":141,"type":21},250,[24],"The objective of this feasibility study is to evaluate the safety and effectiveness of the FARAFLEX mapping and pulsed field ablation (PFA) catheter, a novel catheter in treating persistent atrial fibrillation (PersAF) or symptomatic Paroxysmal Atrial Fibrillation (PAF).",[32,29,28],{"date":146,"type":38},"2026-06-29",{"date":148,"type":38},"2025-02-17",{"date":150,"type":21},"2027-09-15",{"name":99,"class":45},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":77},"100639755","evaluation-of-the-faraflex-mapping-and-pulsed-field-ablation-system-in-subjects-with-atrial-fibrillation-100639755","NCT07575269","Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation","Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation - A Global Prospective Single Arm Study","FARADIGM","Inclusion Criteria:\n\n1. At least 18 years old (or older if required by local law)\n2. Symptomatic, documented, drug-refractory paroxysmal or persistent atrial fibrillation (AF).\n3. Willing and capable of providing written informed consent\n4. Willing and able to comply with all follow-up assessments and study procedures at an approved investigational site\n\nExclusion Criteria:\n\n1. Any of the following atrial conditions:\n\n   1. Left atrial anteroposterior diameter of at least 5.5 cm, or if not available, non-indexed volume greater than 100 mL\n   2. Any prior atrial endocardial, epicardial, or surgical ablation for atrial arrhythmia (excluding right-sided Supraventricular Tachycardia (SVT) or Cavo-Tricuspid Isthmus (CTI)-dependent flutter)\n   3. Any prior atrial surgery\n   4. Current atrial myxoma\n   5. Pulmonary vein abnormality, stenosis, or prior stenting (common and middle pulmonary veins allowed)\n   6. Current left atrial thrombus\n2. Any of the following cardiovascular conditions:\n\n   1. History of sustained ventricular tachycardia or ventricular fibrillation\n   2. Atrial fibrillation secondary to reversible or non-cardiac causes (e.g., electrolyte imbalance, thyroid disease, alcohol)\n   3. Presence of any of the following cardiac devices or implants:\n\n      * Current or anticipated pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy device\n      * Current implantable loop recorder other than LUX-Dx\n      * Prior interatrial baffle or septal closure device\u002Fpatch (Patent Foramen Ovale (PFO)or Atrial Septal Defect (ASD))\n      * Left atrial appendage closure or occlusion device\n   4. Clinically significant valvular disease, including:\n\n      * Any cardiac valve prosthesis, ring, repair, or clip\n      * Moderate to severe mitral stenosis\n      * Moderate to severe aortic stenosis\n      * Severe mitral regurgitation\n      * Severe tricuspid regurgitation\n   5. Hypertrophic or amyloid cardiomyopathy\n   6. Presence of Inferior Vena Cava (IVC) filter, inability to obtain vascular access, or contraindication to femoral access\n   7. Awaiting cardiac transplantation or other cardiac surgery within 12 months (left atrial appendage closure\u002Focclusion procedures allowed no less than (≥) 60 days after index procedure)\n   8. Severe right ventricular dysfunction per investigator assessment\n3. Any of the following congenital conditions:\n\n   1. Congenital heart disease with clinically significant residual anatomic or conduction abnormalities, or channelopathies\n   2. Known congenital methemoglobinemia\n   3. Known G6PD deficiency\n4. Any of the following medical history conditions:\n\n   1. Solid organ or hematologic transplant, or under evaluation for transplant\n   2. History or current evidence of hemi-diaphragmatic paralysis or paresis\n   3. Prinzmetal angina or severe non-revascularizable coronary disease\n   4. Known coagulopathy or bleeding disorder\n   5. Renal insufficiency, history of dialysis, or renal transplant\n   6. Known allergic reaction to nitroglycerin (excluding hypotension)\n   7. Required use of phosphodiesterase inhibitors within 24 hours of the ablation procedure\n   8. Active spinal cord stimulator\n5. Any of the following baseline conditions:\n\n   1. NYHA Class III or IV heart failure\n   2. Left ventricular ejection fraction (LVEF) less than 40% within 12 months\n   3. CHA2DS2-VASc score greater than or equal to 5\n   4. Body mass index (BMI) greater than 45.0\n   5. Contraindication to or unwillingness to use systemic anticoagulation peri-procedurally\n   6. Pregnant or lactating at time of procedure\n   7. Severe lung disease, pulmonary hypertension, or oxygen-dependent lung disease\n   8. Active malignancy (excluding squamous cell carcinoma)\n   9. Clinically significant gastrointestinal disease (e.g., severe or erosive esophagitis, uncontrolled reflux, gastroparesis, esophageal candidiasis, active gastroduodenal ulceration)\n   10. Known Active systemic infection\n   11. Life expectancy of less than 1 year\n   12. Concurrent enrollment in another investigational study or registry that may interfere with this study (exceptions include mandatory governmental registries or purely observational registries with sponsor approval)\n6. Any of the following events within 90 days prior to consent:\n\n   1. Myocardial infarction, unstable angina, or coronary intervention\n   2. Pericarditis or symptomatic pericardial effusion\n   3. Gastrointestinal bleeding\n   4. Cardiac surgery\n   5. Stroke, Transient Ischemic Attack (TIA), or intracranial bleeding\n   6. Any active non-neurologic thrombus and\u002For thromboembolic event\n   7. Carotid stenting or endarterectomy\n   8. Heart failure hospitalization\n   9. Uncontrolled diabetes mellitus or HbA1c greater than 8.0%\n7. Other conditions:\n\n   1. Unwillingness to receive, or unable to tolerate, a subcutaneous, chronically inserted ICM from the LUX-Dx family of devices\n   2. Any medical condition that, in the investigator's opinion, would interfere with study participation, increase risk, or affect data interpretation",{"count":161,"type":21},571,[24],"The goal of this clinical trial is to learn if the FARAFLEX™ Mapping and pulsed field ablation (PFA) System can safely and effectively treat symptomatic, drug-refractory Paroxysmal atrial fibrillation (PAF) and Persistent atrial fibrillation (PersAF). The main question it aims to answer is:\n\nIs the FARAFLEX Mapping and PFA System a safe and effective treatment for patients?\n\nParticipants will undergo an ablation procedure using the FARAFLEX Mapping and PFA System.",[165,29],"Paroxysmal Atrial Fibrillation (PAF)",[167],"pulsed field ablation","2026-06-25",{"date":146,"type":38},{"date":171,"type":21},"2026-06-12",{"date":173,"type":21},"2030-01-01",{"name":99,"class":45},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":182,"sex":17,"minAge":18,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":187,"conditions":188,"keywords":192,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":77},"100528802","convergent-ablation-plus-left-atrial-appendage-isolation-for-the-treatment-of-persistent-atrial-fibrillation-100528802","NCT06165510","Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation","CLIP-AF","Inclusion Criteria:\n\n* Age \\> 18 years; \\\u003C 80 years\n* Persistent AF \\> 1-year duration\n* Left atrium size \\\u003C 6cm\n* Pts should be able to provide written informed consent.\n\nExclusion Criteria:\n\n* Subjects currently enrolled in another investigational study except in case of observational registry with no associated treatments.\n* Subject has a reversible cause of AF or transient AF\n* Subject is absent of LAA or if the LAA is previously surgically ligated\n* Subject has had previous cardiac surgery or abdominal surgery.\n* Subject has contraindication to anticoagulation.\n* Patients with hypertrophic cardiomyopathy.\n* Patients with significant valve disease.\n* Subject has had previous catheter or surgical ablation",true,"80 Years",{"count":185,"type":21},48,[24],"A randomised controlled clinical trial to assess efficacy of convergent ablation with the LARIAT procedure, as compared to standard endocardial catheter ablation in patients with long-standing persistent atrial fibrillation (AF).",[29,189,190,191],"Atrial Fibrillation, Persistent","Atrium; Fibrillation","Atrial Arrhythmia",[193,194,195,196,197],"Catheter ablation","Convergent procedure","Left atrial appendage","Hybrid ablation","Cardiac arrhythmias","2026-06-24",{"date":168,"type":38},{"date":201,"type":38},"2024-08-02",{"date":203,"type":21},"2026-11",{"name":205,"class":206},"Barts & The London NHS Trust","OTHER",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":183,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":77},"100601167","pvi-alone-vs-pvi-and-linear-ablation-for-persistent-atrial-fibrillation-prompt-af-ii-100601167","NCT07106970","PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II)","Linear Ablation Added to Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone Using Pulsed Field Ablation for Persistent Atrial Fibrillation: a Multi-center Randomized Controlled Trial","Inclusion Criteria:\n\nStudy subjects are required to meet all the following inclusion criteria:\n\n1. Subjects with an age range of 18 years or above and 80 years or below.\n2. Subjects have symptomatic, drug-resistant, persistent AF, defined as:\n\n   1. Symptomatic: these symptoms include but not limited to palpitations, presyncope, syncope, fatigue, and shortness of breath.\n   2. Drug-resistant: effectiveness failure of, intolerance to, or specific contraindication to at least one AAD.\n   3. Persistent: continuous AF for \\> 90 days, i) with a minimum a physician's note confirming the diagnosis AND,within 180 days of Enrollment Date, either a 24-hour or longer continuous ECG recording confirming continuous AF OR Two ECGs showing continuous AF taken at least 90 days apart.\n3. Subjects undergoing a first-time ablation procedure for AF.\n4. Subjects who are willing and capable of providing ICF and participating in all testing associated with this study.\n\nExclusion Criteria:\n\n1. AF that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible\u002Fnon-cardiac causes.\n2. Left atrial anteroposterior diameter ≥ 6.0 cm by transthoracic echocardiography (TTE) within 3 months prior the procedure.\n3. Heart failure with left ventricular ejection fraction (LVEF) \\\u003C 30% by TTE within 3 months prior the procedure.\n4. LA thrombus detected by Transesophageal Echocardiography (TEE) or cardiac CT within one day before the procedure or Intracardiac Echocardiography (ICE) before atrial septal puncture during the procedure.\n5. Current or anticipated pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy devices, mechanical valve, interatrial baffle, closure device, patch, or patent foramen oval occlude, left atrial appendage closure at the time of ablation.\n6. Any of the following events within 90 days of the Consent Date:\n\n   1. Myocardial infarction, unstable angina or coronary intervention or any cardiac surgery\n   2. Pericarditis or symptomatic pericardial effusion\n   3. Gastrointestinal bleeding\n   4. Stroke, transient ischemic attack (TIA), or intracranial bleeding or any non-neurologic thromboembolic event\n7. Contraindication to, or unwillingness to use systemic anticoagulation.\n8. Subjects cannot be removed from Class I\u002FIII AAD for reasons other than atrial arrhythmia.\n9. Women of childbearing potential who are pregnant or lactating.\n10. Renal insufficiency if an estimated glomerular filtration rate (eGFR) is \\\u003C 30 mL\u002Fmin\u002F1.73 m2, or with any history of renal dialysis or renal transplant.\n11. Conditions that in the investigator's medical opinion would interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.\n12. Predicted life expectancy less than 12 months.",{"count":215,"type":21},640,[24],"This study is a prospective, multicenter, open-label, randomized controlled trial to investigate whether a linear ablation in addition to pulmonary vein isolation (PVI) outperforms PVI alone using pulsed field ablation (PFA) in maintaining sinus rhythm for persistent atrial fibrillation (PerAF)",[29],"2026-06-16",{"date":221,"type":38},"2026-06-17",{"date":223,"type":38},"2025-08-28",{"date":225,"type":21},"2028-04-30",{"name":99,"class":45},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":183,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":241,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":250,"leadSponsor":252,"locationsCount":77},"100622315","tirzepatide-to-reduce-recurrence-and-burden-after-ablation-of-atrial-fibrillation-100622315","NCT07382024","Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation","Tirzepatide to Reduce Recurrence and Burden After Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Trial","TREAT-AF","Inclusion Criteria:\n\n1. Age between 18 and 80 years.\n2. Diagnosed with persistent atrial fibrillation and scheduled for de novo catheter ablation.\n3. Body mass index (BMI) ≥27 kg\u002Fm² at screening accompanied by at least one weight-related comorbidity (including cardiovascular disease, hypertension, dyslipidemia, or prediabetes).\n4. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Long-standing AF or marked left atrial enlargement (persistent AF duration \\> 5 years or left atrial anterior-posterior diameter \\> 50 mm).\n2. AF secondary to reversible causes (e.g., hyperthyroidism, acute infection, acute pulmonary embolism, recent cardiac surgery).\n3. Severe structural heart disease that may significantly affect ablation outcomes (e.g., hypertrophic cardiomyopathy, rheumatic valvular disease, dilated cardiomyopathy).\n4. Planned major non-AF-related surgery or interventional procedure within 3 months.\n5. Other arrhythmias requiring chronic antiarrhythmic drug therapy.\n6. Intracardiac thrombus or any contraindication to catheter ablation as judged by the investigator.\n7. Active systemic infection at screening.\n8. Contraindications to tirzepatide or GLP-1\u002FGIP receptor agonists (e.g., prior serious hypersensitivity, personal or family history of medullary thyroid carcinoma or MEN2, history of clinically significant pancreatitis, severe gastrointestinal disease that may impair tolerance or absorption).\n9. Poorly controlled type 1 diabetes, recent diabetic ketoacidosis, end-stage renal disease requiring dialysis, or severe hepatic dysfunction judged clinically significant.\n10. Pregnancy, breastfeeding, or women of childbearing potential unwilling or unable to use adequate contraception during the study.\n11. Participation in another interventional clinical study within 30 days prior to screening or planned participation during the study period.\n12. Any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation, including inability to comply with study procedures or follow-up.",{"count":87,"type":21},[24],"The goal of this clinical trial is to determine whether tirzepatide can reduce atrial fibrillation (AF) burden after catheter ablation in overweight or obese patients with persistent AF. It will also evaluate the effects of tirzepatide on body weight, metabolic risk factors, and clinical outcomes, as well as its safety and tolerability in this population.\n\nThe main questions it aims to answer are:\n\n1. Does peri-procedural treatment with tirzepatide reduce AF burden at 3 months after de novo catheter ablation, as measured by 7-day continuous ECG patch monitoring?\n2. Does tirzepatide lead to greater weight loss and improvement in metabolic parameters compared with standard care alone?\n3. Does tirzepatide reduce AF recurrence and cardiovascular events during 12 months of follow-up? Researchers will conduct a multi-center, open-label, endpoint-blinded, randomized controlled trial in adults aged 18-80 years with persistent AF and body mass index ≥25 kg\u002Fm² who are scheduled for de novo catheter ablation. Participants will be randomized 1:1 to receive either tirzepatide plus standard peri-procedural and post-ablation care or standard care alone.\n\nParticipants in the tirzepatide group will receive subcutaneous tirzepatide 2.5 mg once weekly starting about 4 weeks before ablation and continuing for 3 months afterward, for a total treatment duration of approximately 4 months. All participants will be followed at 1, 2, 3, 6, and 12 months after ablation, with detailed assessment of AF burden, AF recurrence, echocardiographic parameters, metabolic profile, quality of life by the AFEQT questionnaire, and safety events.",[239,29,240],"Atrial Fibrillation Ablation","Obesity & Overweight",[123,193,242,243,244,245,246],"Tirzepatide","Overweight and obesity","AF burden","Recurrence","Quality of life","2026-06-10",{"date":171,"type":38},{"date":219,"type":21},{"date":251,"type":21},"2028-07-31",{"name":253,"class":206},"National Taiwan University Hospital",{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":77},"100591859","evaluation-of-the-efficacy-of-pulmonary-vein-isolation-by-pulsed-field-ablation-in-persistent-atrial-fibrillation-a-multicenter-study-with-follow-up-by-implantable-cardiac-monitor-100591859","NCT06985901","Evaluation of the Efficacy of Pulmonary Vein Isolation by Pulsed-field Ablation in Persistent Atrial Fibrillation: a Multicenter Study With Follow-up by Implantable Cardiac Monitor","PersAF ICM","Inclusion Criteria:\n\n* Symptomatic persistent AF (continuous episode sustained beyond 7 days)\n* Refractory, intolerant or unwilling to take ADT\n* Signed informed consent\n* Affiliation to medical social coverage.\n\nNon inclusion Criteria:\n\n* Persistent long-term atrial fibrillation with ongoing episode continuous for more than 3 years;\n* Left ventricular ejection fraction ≤ 15% ;\n* Stage IV of the New York Heart Association classification;\n* Previous atrial ablation outside the cavotricuspid isthmus;\n* Wearer of an implantable electronic cardiac prosthesis (pacemaker or defibrillator; MCI)\n* Hypertrophic heart disease other than hypertensive hypertrophic heart disease;\n* Severe valvular heart disease, including the presence of a mechanical mitral valve or any mitral surgery;\n* Congenital heart disease, including atrial septal defect, patent foramen ovale treated by percutaneous closure with atrial septal prosthesis;\n* Presence of cardiac thrombus;\n* Myocardial infarction or percutaneous coronary angioplasty within the last 6 months;\n* Cardiac surgery within the last 6 months;\n* Systemic thromboembolic event less than 6 months ago;\n* Pulmonary embolism less than 6 months ago or pulmonary hypertension requiring specific treatment;\n* Inability to read independently\n* Vulnerable patient: minor, patient under curatorship or guardianship",{"count":262,"type":21},60,[24],"Atrial fibrillation (AF) is the most common sustained arrhythmia in adult population. According to current guidelines for the management of AF, radiofrequency (RF) ablation (including at least pulmonary vein isolation \\[PVI\\]) is a validated therapeutic option for persistent AF. Recently, Pulsed-field ablation (PFA) - a new non-thermal energy - has been used to treat paroxysmal and persistent AF with a high success rate in observational studies. This new technology is based on tissue-specificity on myocardium, avoiding collateral damages on adjacent structures. Before confirming a superiority of PFA over existing thermal energies, prospective studies concerning an exclusive population of persistent AF patients are needed, with rigorous assessment of the recurrences using continuous monitoring (insertable cardiac monitor \\[ICM\\]). PFA efficacy using ICM has never been evaluated. Before considering PFA in therapeutic strategies through large-scale randomized studies using rigorous monitoring of recurrences, preliminary studies are needed in a persistent AF population-only. This pilot cohort study will provide solid data of PFA efficacy (using continuous monitoring of recurrences) for future randomized studies.",[29],{"date":267,"type":38},"2026-06-11",{"date":269,"type":38},"2026-04-13",{"date":271,"type":21},"2030-04-13",{"name":273,"class":206},"Centre Hospitalier Universitaire de Nice",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":183,"enrollmentInfo":282,"targetDuration":284,"studyType":285,"phases":4,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":77},"100638730","pulsed-field-ablation-versus-radiofrequency-ablation-effects-of-pulmonary-vein-isolation-combined-with-left-atrial-posterior-wall-isolation-on-postoperative-gastric-motility-in-patients-with-persistent-atrial-fibrillation-100638730","NCT07612241","Pulsed Field Ablation Versus Radiofrequency Ablation: Effects of Pulmonary Vein Isolation Combined With Left Atrial Posterior Wall Isolation on Postoperative Gastric Motility in Patients With Persistent Atrial Fibrillation","A Comparative Study on the Effects of Pulmonary Vein Isolation Combined With Left Atrial Posterior Wall Isolation Via Pulsed Field Ablation Versus Radiofrequency Ablation on Postoperative Gastric Motility in Patients With Persistent Atrial Fibrillation","PFA-GM","Inclusion Criteria:\n\n* Age 18-80 years\n* Diagnosed with persistent atrial fibrillation (AF) according to current guidelines\n* Undergoing first-time catheter ablation (PFA or RF) with planned pulmonary vein isolation plus left atrial posterior wall isolation\n* Able to understand and sign informed consent\n* Able to complete radionuclide gastric emptying scintigraphy and symptom questionnaires\n\nExclusion Criteria:\n\n* Previous AF ablation or cardiac surgery\n* History of gastroparesis or severe gastrointestinal disease\n* Prior upper gastrointestinal surgery\n* Use of prokinetic or antisecretory medications within 4 weeks before enrollment\n* Severe renal\u002Fhepatic dysfunction or active malignancy\n* Pregnant or breastfeeding women\n* Inability to comply with study procedures or follow-up",{"count":283,"type":21},20,"7 Days","OBSERVATIONAL","This is a single-center, prospective, matched cohort study comparing the effect of Pulsed Field Ablation (PFA) versus Radiofrequency Ablation (RF) on postoperative gastric motility in patients with persistent atrial fibrillation (AF). A total of 20 patients will be enrolled in a 1:1 matched design (10 PFA, 10 RF), matched by age, gender, left atrial diameter, AF duration, and diabetes history. All patients will undergo pulmonary vein isolation (PVI) plus left atrial posterior wall isolation (LAPWI).\n\nThe primary outcome is gastric emptying assessed by radionuclide imaging preoperatively and at 48 hours post-ablation. Secondary outcomes include gastrointestinal symptom scores: PAGI-SYM, GSRS, and GerdQ measured before ablation and at 7 days post-procedure.\n\nPatients with prior AF ablation, upper gastrointestinal surgery, gastroparesis, or recent use of gastrointestinal medications are excluded. The study period is from January 30, 2026 to July 30, 2026.\n\nThis study aims to evaluate whether PFA is associated with better gastric motility preservation compared with conventional RF ablation in persistent AF patients undergoing extended PVI plus posterior wall isolation.",[29],"2026-05-28",{"date":290,"type":38},"2026-06-02",{"date":292,"type":21},"2026-05-31",{"date":294,"type":21},"2026-12-31",{"name":296,"class":206},"Xijing Hospital",{"id":298,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":25,"conditions":301,"keywords":302,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":307,"leadSponsor":308,"locationsCount":309},"100633202",{"count":20,"type":21},[24],[27,28,29],[31,32,33,29],"2026-05-22",{"date":305,"type":38},"2026-05-27",{"date":40,"type":38},{"date":42,"type":21},{"name":44,"class":45},13,{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":22,"phases":319,"briefSummary":320,"conditions":321,"keywords":322,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":332},"100606902","balloon-based-pfa-ablation-post-approval-outcomes-for-paf-and-persaf-100606902","NCT07181590","BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF","BLAST-OFF","Inclusion Criteria:\n\n1. Documented symptomatic PAF or PersAF. Documentation requirements are as follows:\n\n   Paroxysmal:\n   * Physician's note indicating recurrent self-terminating AF AND\n   * One electrocardiographically documented PAF episode within 12 months prior to enrollment.\n\n   Persistent: Continuous AF sustained beyond 7 days and less than 1 year that is documented by\n   * Physician's note, AND either\n   * 24-hour Holter within 360 days prior to enrollment, showing continuous AF, OR\n   * Two electrocardiograms (from any form of rhythm monitoring) showing continuous AF:\n\n     * That are taken at least 7 days apart but less than 12 months apart\n     * If electrograms are more than 12 months apart, there must be one or more Sinus Rhythm recordings in between or within 12 months prior to consent\u002Fenrollment\n     * The most recent electrocardiogram must be within 180 days of enrollment.\n\n   NOTE: Documented evidence of the AF episode must either be continuous AF on a 12-lead ECG or include at least 30 seconds of AF from another ECG device.\n2. Plans to undergo a de novo ablation procedure with the Volt PFA Catheter due to symptomatic PAF or PersAF and is refractory, intolerant, or contraindicated to at least one Class I-IV AAD medication\n3. At least 18 years of age\n4. Able and willing to comply with all trial requirements including pre-procedure, post- procedure, and follow-up testing and requirements\n5. Informed of the nature of the trial, agreed to its provisions, and has provided written informed consent as approved by the Institutional Review Board\u002FEthics Committee (IRB\u002FEC) of the respective clinical trial site.\n\nExclusion Criteria\n\n1. Arrhythmia due to reversible causes including thyroid disorders, acute alcohol intoxication, electrolyte imbalance, severe untreated sleep apnea, and other major surgical procedures in the preceding 90 days\n2. Known presence of cardiac thrombus\n3. Known Left ventricular ejection fraction \\\u003C 35% as assessed with echocardiography within 360 days of index procedure\n4. New York Heart Association (NYHA) class III or IV heart failure\n5. Pregnant, nursing, or planning to become pregnant during the clinical investigation follow-up period\n6. Patients who have had a ventriculotomy or atriotomy within the preceding 30 days of procedure\n7. Myocardial infarction (MI), acute coronary syndrome, percutaneous coronary intervention (PCI), or valve or coronary bypass grafting surgery within preceding 90 days\n8. Unstable angina\n9. Stroke or TIA (transient ischemic attack) within the last 90 days\n10. Heart disease in which corrective surgery is anticipated within 180 days after procedure\n11. History of blood clotting or bleeding abnormalities including thrombocytosis, thrombocytopenia, bleeding diathesis, or suspected anti-coagulant state\n12. Contraindication to long term anti-thromboembolic therapy\n13. Patient unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation\n14. Previous left atrial surgical or left atrial catheter ablation procedure (including LAA closure device)\n15. Severe mitral regurgitation (regurgitant volume ≥ 60 mL\u002Fbeat, regurgitant fraction ≥ 50%, and\u002For effective regurgitant orifice area ≥ 0.40cm2).\n16. Previous tricuspid or mitral valve replacement or repair\n17. Patients with prosthetic valves\n18. Patients with a myxoma\n19. Patients with an interatrial baffle or patch as the transseptal puncture could persist and produce an iatrogenic atrial shunt\n20. Stent, constriction, or stenosis in a pulmonary vein\n21. Rheumatic heart disease\n22. Hypertrophic cardiomyopathy\n23. Diagnosed with amyloidosis or atrial amyloidosis\n24. Active systemic infection\n25. Renal failure requiring dialysis\n26. Severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms\n27. Presence of an implanted LAA closure device\n28. Patient is currently participating in another clinical study that may confound the results of this of this post market evaluation; for example, enrolled in another study with an active treatment arm\n29. Unlikely to survive the protocol follow up period of 12 months\n30. Presence of other medical, anatomic, comorbid, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.\n31. Individuals without legal authority\n32. Individuals unable to read or write",{"count":318,"type":21},300,[24],"This study is designed to obtain real-world clinical evidence on the safety and effectiveness of the Volt PFA System in various use cases, with a sub study designed to address additional clinical evidence needs in electrophysiology.",[28,191,32,29],[33,29,60,323],"Persistent Field Ablation","2026-05-21",{"date":326,"type":38},"2026-05-26",{"date":328,"type":38},"2025-12-11",{"date":330,"type":21},"2027-08",{"name":44,"class":45},22,{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":182,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":342,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":77},"100639507","a-study-on-the-therapeutic-value-of-additional-left-atrial-posterior-wall-isolation-guided-by-voltage-mapping-in-persistent-atrial-fibrillation-100639507","NCT07590661","A Study on the Therapeutic Value of Additional Left Atrial Posterior Wall Isolation Guided by Voltage Mapping in Persistent Atrial Fibrillation.","Prospective, Multicenter, Randomized Controlled Study on the Therapeutic Value of Additional Left Atrial Posterior Wall Isolation Guided by Voltage Mapping in Persistent Atrial Fibrillation.","Inclusion Criteria:\n\n1. Older than 18 years.\n2. Diagnosed as persistent atrial fibrillation (AF); Definition: At least one episode of persistent AF was recorded on dynamic electrocardiogram (ECG) data within 12 months prior to enrollment, or other clinical evidence supporting persistent AF episodes lasting more than 7 days.\n3. Subjects are able to understand the purpose of the study, voluntarily participate in the study and sign the informed consent, and are willing to complete the follow-up according to the requirements of the program.\n\nExclusion Criteria:\n\n1. Atrial fibrillation is secondary to thyroid disease or other reversible factors.\n2. Evidence of left atrial or left atrial appendage thrombus on imaging examination.\n3. Rheumatic heart disease or the presence of moderate to severe mitral stenosis or regurgitation.\n4. Left ventricular ejection fraction \\\u003C40% or New York Heart Association (NYHA) class III\u002FIV.\n5. Left atrial anteroposterior diameter \\>55 mm.\n6. Unstable angina.\n7. Myocardial infarction (MI), coronary artery bypass grafting (CABG), or percutaneous coronary intervention (PCI) within 3 months prior to enrollment.\n8. Previous catheter ablation or surgical ablation for atrial fibrillation.\n9. History of prior left atrial appendage closure, patent foramen ovale closure, atrial septal defect closure, or repair surgery.\n10. Implantation of a mechanical mitral valve prosthesis or metallic annuloplasty rings.\n11. Presence of intracardiac thrombus, space-occupying lesions, or other abnormalities that preclude vascular access or catheter manipulation.\n12. Contraindications to anticoagulation or history of coagulation disorders\u002Fabnormal bleeding.\n13. Active systemic infection.\n14. Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m² or history of renal dialysis.\n15. Severe hepatic dysfunction.\n16. Pregnancy or breastfeeding.\n17. Life expectancy \\\u003C12 months (e.g., advanced malignancy).\n18. Current or anticipated participation in other drug or device clinical trials.\n19. Any other condition or abnormality deemed by the investigator to warrant exclusion.",{"count":341,"type":21},350,[24],"This prospective, multicenter, randomized controlled study was designed to investigate the feasibility, efficacy and safety of pulsed field ablation (PFA) strategies for persistent atrial fibrillation. For patients with persistent atrial fibrillation and normal left atrial substrate, pulmonary vein isolation combined with superior vena cava isolation will be performed. For those with abnormal left atrial substrate, two strategies will be adopted: pulmonary vein isolation plus superior vena cava isolation, and pulmonary vein isolation combined with superior vena cava isolation and left atrial posterior wall isolation. Long-term follow-up will be conducted to observe the long-term clinical outcomes.",[29],"2026-05-12",{"date":347,"type":38},"2026-05-15",{"date":349,"type":21},"2026-04-30",{"date":351,"type":21},"2029-02",{"name":353,"class":45},"Hangzhou Dinova EP Technology Co., Ltd",{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":22,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":376},"100327687","medtronic-terminate-af-study-100327687","NCT03546374","Medtronic Terminate AF Study","Irrigated Radio Frequency Ablation to Terminate Non-Paroxysmal Atrial Fibrillation (Terminate AF Study)","Inclusion Criteria:\n\n* History of non-paroxysmal AF (persistent or longstanding persistent)\n* Concomitant indication for non-emergent open-heart surgery, eg,\n\n  1. Coronary artery bypass grafting\n  2. Valve repair or replacement\n* Able to take the anticoagulant warfarin or novel oral anticoagulants (NOAC)\n\nExclusion Criteria:\n\n* Wolff-Parkinson-White syndrome\n* New York Heart Association (NYHA) Class = IV\n* Left Ventricular Ejection Fraction ≤ 30%\n* Need for emergent cardiac surgery (ie, cardiogenic shock) or redo open heart surgery\n* Previous AF ablation, atrioventricular (AV) -nodal ablation, or surgical Maze procedure\n* Contraindication for anticoagulation therapy\n* Left atrial diameter \\> 6.0 cm\n* Preoperative need for an intra-aortic balloon pump or intravenous inotropes\n* Renal failure requiring dialysis or hepatic failure\n* Life expectancy of less than 1 year\n* Predicted risk of operative mortality \\>10% as assessed by STS Risk Calculator\n* Pregnancy or desire to be pregnant within 12 months of the study treatment\n* Current diagnosis of active systemic infection\n* Active endocarditis\n* Documented MI 30 days prior to study enrollment\n* Current or planned participation in an investigational or observational drug or device trial related to the treatment of atrial arrhythmias",{"count":362,"type":21},160,[24],"The purpose of this study is to demonstrate the safety and effectiveness of the Cardioblate iRF and CryoFlex hand held devices for the treatment of non-paroxysmal atrial fibrillation (AF).",[29,366],"Longstanding Persistent Atrial Fibrillation","2026-05-07",{"date":369,"type":38},"2026-05-14",{"date":371,"type":38},"2018-11-15",{"date":373,"type":21},"2026-12",{"name":375,"class":45},"Medtronic Cardiac Surgery",15,{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":22,"phases":387,"briefSummary":388,"conditions":389,"keywords":390,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":399,"locationsCount":4},"100627186","circumferential-pulmonary-venous-isolation-combined-with-bachmann-bundle-modification-versus-circumferential-pulmonary-venous-isolation-for-persistent-atrial-fibrillation-100627186","NCT07445360","Circumferential Pulmonary Venous Isolation Combined With Bachmann Bundle Modification Versus Circumferential Pulmonary Venous Isolation for Persistent Atrial Fibrillation","A Multicenter, Prospective, Randomized Controlled Study of Circumferential Pulmonary Venous Isolation Combined With Bachmann Bundle Modification Versus Circumferential Pulmonary Venous Isolation for Persistent Atrial Fibrillation","Inclusion Criteria:\n\n1. Subjects≥ 18 years old and ≤ 75 years old;\n2. the subject was diagnosed with persistent atrial fibrillation (duration of ≥6 months and ≤ 3 years);\n3. Able to understand the purpose of the trial, voluntarily participate in this study, the subject or his legal representative signed the informed consent form, and was willing to complete the follow-up according to the requirements of the protocol.\n\nExclusion Criteria:\n\n1. Previous atrial fibrillation catheter ablation therapy, left atrial appendage closure or atrial fibrillation surgery;\n2. atrial fibrillation secondary to electrolyte imbalances, thyroid disease or other reversible disease, or non-cardiac causes;\n3. Left atrial or left atrial appendage thrombus (confirmed by esophageal ultrasound or CT examination);\n4. Patients with pulmonary vein stenosis or pulmonary vein stents implanted;\n5. Have had atrial septal repair or atrial myxoma;\n6. Severe structural heart disease (such as moderate to severe mitral regurgitation, dilated cardiomyopathy, hypertrophic cardiomyopathy, severe heart valve disease);\n7. Cardiac ultrasound showed that the diameter of the left atrium was ≥50mm\n8. New York College of Cardiology (NYHA) cardiac function grades III and IV; LVEF\\\u003C40%；\n9. Those with cerebrovascular diseases (including stroke, transient ischemic attack) in the past 3 months;\n10. Those who have had cardiovascular events in the past 3 months (including acute myocardial infarction, coronary intervention or heart bypass);\n11. surgery, prosthetic valve replacement or repair, atrial or ventriculotomy;\n12. Those with acute or severe systemic infection;\n13. Combined with severe liver and kidney insufficiency (AST or ALT≥ 3 times the upper limit of normal; SCr\\>3.5mg\u002Fdl or Ccr\\\u003C30ml\u002Fmin);\n14. Those with obvious bleeding tendency and hematologic diseases, or contraindications to anticoagulation;\n15. Patients with malignant tumors and end-stage diseases with a life expectancy of \\\u003C 12 months; After chemotherapy or radiotherapy for malignant tumors;\n16. The subject is a female who is pregnant or lactating or cannot use contraception during the trial;\n17. The subject has participated in clinical trials of other drugs or devices during the same period;\n18. Abnormalities or diseases that, in the opinion of the investigator, should be excluded from the scope of enrollment in this study.","75 Years",{"count":386,"type":21},320,[24],"This study is a prospective, randomized controlled, single-blind, multicenter study design. To evaluate the safety and efficacy of traditional pulmonary vein isolation (PVI) alone and PVI combined with Bachmann bundle ablation on persistent atrial fibrillation.\n\nAccording to the treatment strategy, they were divided into two groups. Control group: circumferential PVI alone group (CPVI). Experimental group: CPVI combined with Bachmann bundle ablation group (CPVI-BBM).",[29],[391,392],"Circumferential pulmonary venous isolation","Bachmann bundle modification","2026-05-06",{"date":395,"type":38},"2026-05-11",{"date":397,"type":21},"2026-05-01",{"date":73,"type":21},{"name":400,"class":206},"Shenyang Northern Hospital",{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":183,"enrollmentInfo":409,"targetDuration":4,"studyType":22,"phases":410,"briefSummary":411,"conditions":412,"keywords":413,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":4},"100638209","outcomes-of-an-optimized-workflow-with-pulseselect-pulsed-field-ablation-pfa-system-in-paroxysmal-and-persistent-atrial-fibrillation-100638209","NCT07575828","Outcomes of an Optimized Workflow With PulseSelect Pulsed Field Ablation (PFA) System in Paroxysmal and Persistent Atrial Fibrillation","Outcomes of an Optimized Workflow With PulseSelect Pulsed Field Ablation (PFA) System in Paroxysmal and Persistent Atrial Fibrillation (NEXT PULSE)","NEXT PULSE","Inclusion Criteria:\n\n1. Adults who are ≥18 and ≤80 years of age on the day of enrollment (or older than 18 if required by local law)\n2. A diagnosis of recurrent symptomatic paroxysmal or persistent AF:\n\n   Symptomatic paroxysmal AF: AF that terminates spontaneously or with intervention within 7 days of onset, documented by the following:\n   1. Physician's note indicating at least 2 symptomatic paroxysmal AF episodes occurring within 12 months prior to enrollment; AND\n   2. at least 1 ECG documented AF episode from any form of rhythm monitoring within 12 months prior to enrollment.\n\n   Symptomatic persistent AF: Continuous AF sustained beyond 7 days and less than 1 year, documented by the following:\n   1. Physician's note indicating at least 1 symptomatic persistent AF episode occurring within 12 months prior to enrollment; AND\n   2. any 24-hour continuous ECG recording documenting continuous AF within 12 months prior to enrollment; OR 2 ECGs from any form of rhythm monitoring taken at least 7 days apart, both showing continuous AF within 12 months prior to enrollment\n3. Willing and able to comply with all baseline and follow-up evaluations for the full length of the study.\n\nExclusion Criteria:\n\n1. Long-standing persistent AF (continuous AF that is sustained \\>12 months)\n2. Paroxysmal AF patients: AF that required three (3) or more distinct cardioversions in the preceding 12 months.\n3. Paroxysmal AF: LA anteroposterior diameter \\> 5.0 cm (by MRI, CT, or TTE) Persistent AF: LA anteroposterior diameter \\> 5.5 cm (by MRI, CT, or TTE)\n4. Any of the following procedures, implants, or conditions at baseline: prior left atrial catheter or surgical ablation, prior left atrial percutaneous interventions including left atrial appendage occlusion, and septal closure devices\n5. Planned LAA closure procedure or implant of a permanent pacemaker, biventricular pacemaker, loop recorder\u002Finsertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function) for any time during the follow-up period\n6. Presence of a permanent pacemaker, biventricular pacemaker, loop recorder\u002Finsertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function)\n7. Patient who is not on oral anticoagulation therapy for at least 3 weeks prior to the ablation procedure\n8. Contraindication to or unwillingness to use systemic anticoagulation\n9. Presence of any pulmonary vein stents\n10. Known pre-existing pulmonary vein stenosis\n11. Prior valvular (surgical or percutaneous) procedure including prosthetic, bioprosthetic, valve replacement, valve repair or valvuloplasty, and any prior atriotomy\n12. Moderate to severe mitral valve or aortic stenosis\n13. Moderate to severe mitral regurgitation (i.e., 3+ or 4+ MR)\n14. Any cardiac surgery, myocardial infarction, PCI \u002F PTCA or coronary artery stenting which occurred during the 3-month interval preceding the consent date\n15. Unstable angina\n16. NYHA Class III or IV congestive heart failure or documented left ventricular ejection fraction (LVEF) less than or equal to 40% measure by acceptable cardiac testing (e.g. TTE), or planned transplant or left ventricular assist device (LVAD)\n17. Severe lung disease, primary pulmonary hypertension, or any lung disease abnormal blood gases or requiring supplemental oxygen\n18. Rheumatic heart disease\n19. Severe thrombocytosis, thrombocytopenia, or any bleeding or clotting disorder\n20. Documented left atrial thrombus on imaging\n21. Active systemic infection or sepsis\n22. Hypertrophic cardiomyopathy\n23. Known reversible causes of AF, including but not limited to uncontrolled hyperthyroidism, severe untreated obstructive sleep apnea, and acute alcohol toxicity\n24. Any cerebral ischemic event (strokes or TIAs) which occurred during the 6-month interval preceding the consent date\n25. Carotid stenting or endarterectomy\n26. History of thromboembolic event within the past 6 months or evidence of intracardiac thrombus at the time of the procedure\n27. Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence\n28. Patient with life expectancy that makes it unlikely 12 months of follow-up will be completed\n29. Current or anticipated participation in any other clinical trial of a drug, device or biologic during the duration of the study not pre-approved by Medtronic\n30. Known allergies or hypersensitivities to adhesives\n31. Body mass index \\> 40 kg\u002Fm2\n32. Atrial myxoma\n33. Significant restrictive or obstructive pulmonary disease or chronic respiratory condition.\n34. Renal insufficiency with an estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m2, or any history of renal failure requiring dialysis or renal transplant\n35. Solid organ or hematologic transplant, or currently being evaluated for an organ transplant\n36. Presence of intramural thrombus, tumor, or other abnormality that precludes vascular access, catheter introduction, or manipulation\n37. Known drug or alcohol dependency\n38. Significant congenital anomaly or medical problem that, in the opinion of the investigator, would preclude enrollment in this study or compliance with follow-up requirements or would impact the scientific soundness of the clinical trial results\n39. Amyloid heart disease (cardiac amyloidosis)",{"count":386,"type":21},[24],"The NEXT PULSE study is a pre-market, prospective, multi-center, non-randomized, interventional clinical study. Adult subjects with symptomatic paroxysmal or persistent AF who provided consent will be enrolled and treated with the PulseSelect PFA System.",[165,29],[27,28,414,415,416,417,60,193,418],"Persistent AF","Symptomatic recurrent AF","Arrhythmia","PulseSelect PFA System","Pulmonary Vein Ablation","2026-05-04",{"date":421,"type":38},"2026-05-08",{"date":423,"type":21},"2026-08",{"date":425,"type":21},"2029-03",{"name":427,"class":45},"Medtronic Cardiac Ablation Solutions",{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":434,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":436,"targetDuration":438,"studyType":285,"phases":4,"briefSummary":439,"conditions":440,"keywords":441,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":451},"100634098","represent-pf-registry-100634098","NCT07535268","REPRESENT-PF Registry","Prospective Multicenter Registry on the Clinical Outcomes and Safety of PFA for Atrial Fibrillation in Underrepresented Minorities (REPRESENT-PF Registry)","REPRESENT-PF","Inclusion Criteria:\n\n* All consecutive patients classified as racial or ethnic minorities undergoing ablation using Boston Scientific FDA approved PFA catheters for AF will be included.\n* De novo ablation for symptomatic paroxysmal and persistent AF (Age ≥ 18) (unless it is a repeat for a patient whose index procedure is also in the registry) who are deemed to be candidates for AF ablation by the investigator.\n* Able and willing to participate in baseline and follow up evaluation over the study period\n* Willing and able to provide informed consent, if applicable.\n\nExclusion Criteria:\n\n* Enrolled in an investigational drug or device clinical trial or any other trial with outlined treatment plan\n* Long standing persistent AF (AF \\> 1 year duration)\n* Repeat ablation, unless index ablation procedure was in the REPRESENT-PF registry\n* Any known contra-indication to ablation procedure at the discretion of the investigator",{"count":437,"type":21},275,"12 Months","This pragmatic, prospective, single-arm, multi-center, observational registry will evaluate the safety and effectiveness of PFA for the treatment of atrial fibrillation in underrepresented minority patients using FDA approved Boston Scientific PFA catheters; all data collected will be standard of care.",[29,33],[33,29,60],"2026-04-09",{"date":444,"type":38},"2026-04-17",{"date":446,"type":38},"2026-03-30",{"date":448,"type":21},"2028-03-01",{"name":450,"class":206},"Vivek Reddy",2,{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":22,"phases":461,"briefSummary":462,"conditions":463,"keywords":464,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":478,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":55},"100615889","conquer-af-protocol-for-redo-ablation-procedures-in-recurrent-paroxysmal-and-persistent-atrial-fibrillation-using-the-sphere-9-catheter-and-affera-ablation-system-conquer-af-100615889","NCT07298473","Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)","Conquer-AF","Inclusion Criteria:\n\n* 1\\. History of a single AF ablation procedure for PAF or PsAF within 3 years prior to enrollment 2. Documented evidence of symptomatic AF, AT or AFL recurrence at least 90 days after subject's de novo ablation procedure, as demonstrated by:\n\n  * A physicians' note indicating at least 1 symptomatic AF, AT, or AFL episode occurring within 12 months prior to the enrollment; and\n  * At least 1 electrocardiographically documented episode of AF, AT, or AFL within 12 months prior to enrollment 3. Adults who are ≥18 years of age on the day of enrollment 4. Willing and able to comply with all study requirements and provide informed consent\n\nExclusion Criteria:\n\n* 1\\. Continuous AF lasting for 12 months or longer 2. LA anteroposterior \\>55 mm (by MRI, CT, or TTE), or if LA diameter not available, non-index volume \\>100 mL for PsAF subjects; OR LA anteroposterior \\>50 mm (by MRI, CT, or TTE), or if LA diameter not available, non-index volume \\>95 mL for PAF subjects 3. Previous left atrial percutaneous interventions including left atrial appendage occlusion and septal closure devices 4. Planned left atrial appendage (LAA) closure procedure, cardiac transplantation or implant of a permanent pacemaker, biventricular pacemaker, loop recorder\u002Finsertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function) for any time during the follow-up period 5. More than 1 previous AF ablation procedure 6. Any prior surgical ablation procedure 7. Patient who is not on oral anticoagulation therapy for at least 3 weeks prior to the ablation procedure 8. Contraindication to or unwillingness to use systemic anticoagulation 9. Severe thrombocytosis, thrombocytopenia, or any bleeding or clotting disorder 10. Presence of a permanent pacemaker, biventricular pacemaker, loop recorder\u002Finsertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function) 11. Presence of any pulmonary vein stents 12. Known pre-existing pulmonary vein stenosis 13. Pre-existing hemidiaphragmatic paralysis 14. Prior valvular (surgical or percutaneous) procedure including prosthetic, bioprosthetic, valve replacement, valve repair or valvuloplasty, or any prior atriotomy 15. Moderate to severe mitral valve or aortic stenosis 16. Moderate to severe mitral regurgitation (i.e., 3+ or 4+ MR) 17. Any cardiac surgery, myocardial infarction, PCI\u002FPTCA or coronary artery stenting which occurred within the 3 months preceding the consent date 18. NYHA Class III or IV congestive heart failure 19. Documented left ventricular ejection fraction (LVEF) ≤40%, measured by acceptable cardiac testing (e.g., TTE) 20. Unstable angina 21. Severe lung disease, primary pulmonary hypertension, or any lung disease requiring supplemental oxygen 22. Rheumatic heart disease 23. Significant restrictive or obstructive pulmonary disease or chronic respiratory condition 24. Presence of left atrial thrombus on imaging 25. Active systemic infection or sepsis 26. Hypertrophic cardiomyopathy 27. Amyloid heart disease 28. Diagnosed atrial myxoma 29. Known reversible causes of AF (e.g., uncontrolled hyperthyroidism, severe untreated obstructive sleep apnea, acute alcohol toxicity or other reversible or non-cardiac cause) 30. Any cerebral ischemic event (strokes or TIAs) which occurred within the preceding 6 months of the consent date through the date of study index redo ablation procedure 31. Carotid stenting or endarterectomy 32. Thromboembolic event within the past 6 months or evidence of intracardiac thrombus at the time of the procedure 33. Body mass index \\> 40 kg\u002Fm2 34. Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence\\* 35. Patient with life expectancy that makes it unlikely 12 months of follow-up will be completed 36. Current or anticipated participation in any other clinical study of a drug, device or biologic during the duration of the study not pre-approved by Medtronic 37. Renal insufficiency with an estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m2, or any history of renal failure requiring dialysis or renal transplant 38. Presence of intramural thrombus, tumor, or other abnormality that precludes vascular access, catheter introduction, or manipulation 39. Presence of an inferior vena cava (IVC) filter (e.g., Greenfield or similar) that would preclude safe transfemoral venous access, catheter passage, or sheath manipulation.\n\n  40\\. Known drug or alcohol dependency 41. Significant congenital anomaly or medical problem that would, in the opinion of the investigator, preclude enrollment, follow-up compliance, or the scientific integrity of the study\n\n  \\*Women who are of child-bearing potential must undergo a pregnancy test after consent and prior to the study index redo ablation procedure, as allowed according to local regulations",{"count":460,"type":21},400,[24],"Conquer-AF is a prospective, multi-center, interventional, non-randomized clinical study that will enroll up to 400 subjects at up to 30 sites across the United States, Europe, and Australia.\n\nSubjects diagnosed with symptomatic recurrent paroxysmal or persistent atrial fibrillation after a single prior ablation procedure will be enrolled in this study. Each subject will undergo a study index redo ablation procedure using the Sphere-9 Catheter and Affera Ablation System and will be followed for 12 months. The expected total study duration (from time of first enrollment to the exit of last enrolled subject) is approximately 2 years.",[27,29,165],[465,466,467,468,469,470,32,33,29,471,472,473,474,475,476,477],"Sphere-9 Catheter","Affera Ablation System","Affera Mapping System","Pulsed Field Ablation (PFA)","Radiofrequency Ablation (RFA)","Dual-Energy Ablation","Redo Ablation","Repeat Ablation","Electrophysiology Mapping","3D Cardiac Mapping","Left Atrial Ablation","Redo AF Ablation","Repeat Ablation Procedures",{"date":269,"type":38},{"date":480,"type":38},"2026-04-08",{"date":482,"type":21},"2028-03-29",{"name":427,"class":45},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":17,"minAge":492,"maxAge":493,"enrollmentInfo":494,"targetDuration":4,"studyType":22,"phases":495,"briefSummary":496,"conditions":497,"keywords":500,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":508,"leadSponsor":510,"locationsCount":77},"100617911","preactive-preconditioning-exercise-intervention-to-improve-symptoms-and-quality-of-life-in-comorbid-atrial-fibrillation-and-hfpef-100617911","NCT07324772","PREACTIVE: Preconditioning Exercise Intervention to Improve Symptoms and Quality of Life in Comorbid Atrial Fibrillation and HFpEF","PREACTIVE: Preconditioning With REsistance and AerobiC Training to ImproVe Exercise Intolerance and Quality of Life in Comorbid Atrial Fibrillation and HFpEF","PREACTIVE","Inclusion Criteria:\n\nAll participants will be age 60 and older, have a primary diagnosis of AF and HFpEF, based on electronic health record review. Patients with persistent AF or Paroxysmal AF are eligible. HFpEF will be defined in accordance to the 2022 AHA\u002FACC\u002FHFSA Guideline using a clinical composite score, the H2FPEF score, in conjunction with diagnostic criteria below:\n\n* Ejection fraction ≥ 50%\n* E\u002Fe' ≥15 by Doppler Echocardiography\n* High H2FpEF score (≥5)\n* Must be in stable medical condition and able to begin an exercise program\n\nExclusion Criteria:\n\n* Valvular heart disease as the primary etiology of heart failure (i.e., severe aortic stenosis or mitral regurgitation),\n* New York Heart Association Stage IV\n* Recent stroke (\\\u003C1 year)\n* Evidence or History of Cardiac amyloidosis\n* Patients with persistent AF and poor rate control (HR \\> 110 at rest)\n* Significant change in cardiac medication or Heart Failure symptoms \\\u003C 2 weeks\n* Unstable or severe angina not controlled during daily activity by pharmacological therapy or at \\\u003C4 METS activity\n* Uncontrolled hypertension (defined as systolic blood pressure \\>200 mm Hg and\u002For diastolic blood pressure\\>110 mm Hg) with medications\n* Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions\n* Hospitalization or urgent care visit \\\u003C 4 weeks\n* Oxygen dependent Chronic Obstructive Pulmonary Disease (COPD)\n* Significant anemia (\\\u003C10 g\u002FdL Hgb)\n* End stage renal replacement therapy associated with the need for dialysis\n* Active treatment for cancer defined as current radiation, chemotherapy, immunotherapy, or cancer recurrence within past 5 years\n* Hospice care and indication of life expectancy less than 2 years\n* Complete dependence confinement to a Wheelchair confinement or requiring a visual impairment or Orthopedic or severe musculoskeletal conditions that would prohibit resistance training or aerobic exercise.\n* Physician diagnosed Alzheimer's disease or Dementia or bipolar or psychotic disorder; Montreal Cognitive Assessment (MoCA) is ≤ 18 (based on participant screening)\n* High levels of physical functioning based the composite short physical performance battery score of ≥10 (out of 12)\n* Planned major surgery, coronary or leg revascularization during the next six months\n* Participation in a supervised exercise program or already engaging in regular exercise\n* Plans to transfer care outside of NU within the study period\n* Unable to consent or commit to requires study procedures\n* Non-English speaking","60 Years","99 Years",{"count":55,"type":21},[24],"Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are very common conditions that often occur together and result in worsening symptoms and reduced quality of life (QoL). Limitations being able to participate in activities of daily living is a primary complaint for AF-HFpEF patients, yet effective strategies to address this issue remain limited. While exercise interventions targeting aerobic training (AT) are recommended for patients with AF and HFpEF, unique challenges exist in this patient population who tend to be older. Specifically, many older patients with AF and HFpEF have muscle weakness, sarcopenia and frailty, that can make aerobic-focused exercise difficult and less tolerable. This study proposes that starting with progressive resistance training (PRT) before aerobic exercise may overcome these issues by improving muscle strength, making AT more manageable, and leading to better health outcomes. The goal of this study is to assess whether a sequential exercise program, named 'PREACTIVE' improves how people feel, decrease the amount of symptoms, and their ability to participate in exercise and activities.\n\nThis study will specifically test a sequenced exercise approach of resistance training followed by aerobic exercise to improve symptoms, and quality of life in AF-HFpEF.",[27,498,29,499],"Atrial Fibrillation (Paroxysmal)","Heart Failure With Preserved Ejection Fraction (HFPEF)",[501,502,503,504],"exercise","exercise capacity","symptom severity","quality of life","2026-04-06",{"date":480,"type":38},{"date":269,"type":21},{"date":509,"type":21},"2027-05",{"name":511,"class":206},"Northwestern University",{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":518,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":183,"enrollmentInfo":520,"targetDuration":4,"studyType":22,"phases":522,"briefSummary":524,"conditions":525,"keywords":526,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":537},"100632048","phase-4-study-on-the-prevention-of-atrial-fibrillation-recurrence-after-ablation-by-qidong-yixin-granule-100632048","NCT07508618","Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule","Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule Based on Multicenter Clinical Trials and Omics Mechanisms","QDYX-AF","Inclusion Criteria:\n\n* Age 18-80 years (inclusive);\n* Diagnosed with non-valvular persistent atrial fibrillation, having failed at least one antiarrhythmic drug treatment, and scheduled to undergo initial ablation;\n* Voluntarily participate in this study and sign an informed consent form. If the subject is unable to read or sign the informed consent form due to reasons such as lack of capacity, the informed consent process must be completed and signed by their legal guardian. If the subject is unable to read the informed consent form (e.g., illiterate subjects), the informed consent process must be witnessed and signed by a witness.\n\nExclusion Criteria:\n\n* Valvular atrial fibrillation or paroxysmal atrial fibrillation\n* NYHA functional class IV or LVEF \\\u003C40%, LA diameter \\>55mm;\n* Moderate to severe left ventricular hypertrophy (wall thickness \\>1.5cm);\n* Patients with acute coronary syndrome or requiring stent implantation\n* Patients with a history of cardiac surgery within the past 6 months or previous catheter ablation\n* Duration of atrial fibrillation ≥5 years;\n* Hyperthyroidism;\n* Patients with atrial fibrillation and cardiomyopathy;\n* Patients with bradyarrhythmia requiring pacemaker implantation\n* Known bleeding diathesis, presence of left atrial\u002Fleft atrial appendage thrombus, or severe hemostasis and coagulation dysfunction\n* Severe hepatic or renal insufficiency ALT ≥3 × ULN or eGFR \\\u003C45 ml\u002Fmin\u002F1.73 m²;\n* Patients allergic to the components of the study drug;\n* Patients who are currently participating or have participated in other interventional clinical studies within the past 3 months.\n* Pregnant or lactating women, or those with an expected lifespan of \\\u003C12 months;\n* Other vulnerable groups, excluding the elderly\u002Filliterate individuals, including those with mental illnesses, cognitive impairments, critically ill patients, etc\n* Any other reasons deemed by the investigator as unsuitable for the patient's participation in this study",{"count":521,"type":21},846,[523],"PHASE4","The goal of this clinical trial is to investigate the efficacy and safety of Qidong Yixin Granules in preventing recurrence in patients after radiofrequency catheter ablation for atrial fibrillation. The main question it aims to answer is:\n\nCan Qidong Yixin Granules reduce the recurrence rate of atrial fibrillation within 1 year in patients undergoing radiofrequency catheter ablation for atrial fibrillation?\n\nParticipants will be randomly assigned, with a 50% chance of being allocated to either the study group or the control group. Regardless of which group a participant is assigned to, researchers will administer Qidong Yixin Granules or placebo within 48 hours after catheter ablation for atrial fibrillation. Group assignment is determined by computer-generated randomization, and no individual has the authority to interfere with the allocation result.\n\nIf a participant is assigned to the study group, they will receive oral Qidong Yixin Granules after atrial fibrillation ablation: one sachet each time, three times daily, for a 12-month treatment course.\n\nIf a participant is assigned to the control group, they will receive oral placebo matching Qidong Yixin Granules after atrial fibrillation ablation: one sachet each time, three times daily, for a 12-month treatment course.\n\nRegardless of the group assignment, all participants will attend outpatient follow-up at 1, 3, 6, 9, and 12 months postoperatively. Electrocardiography (ECG) and ambulatory electrocardiography (Holter monitoring) will be performed at 1, 3, 6, and 12 months after surgery. Transthoracic echocardiography will be conducted at 3 and 12 months postoperatively. Anticoagulation will be administered for at least 3 months after surgery, and subsequent anticoagulation strategies will be determined based on the CHA₂DS₂-VASc score.",[29],[29,527],"QiDongYiXin","2026-03-27",{"date":530,"type":38},"2026-04-02",{"date":532,"type":38},"2026-02-09",{"date":534,"type":21},"2027-08-30",{"name":536,"class":206},"Sir Run Run Shaw Hospital",5,{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":183,"enrollmentInfo":546,"targetDuration":4,"studyType":22,"phases":548,"briefSummary":549,"conditions":550,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":557,"locationsCount":559},"100556812","endocardial-mapping-with-the-coremap-ep-mapping-system-100556812","NCT06529978","Endocardial Mapping With the CoreMap EP Mapping System","Endocardial Mapping With the CoreMap Electrophysiology Mapping System for Persistent Atrial Fibrillation Protocol","INvENI","Inclusion Criteria:\n\n1. Subject has persistent or long-standing persistent AF, at the discretion of the investigator (Phase 1 \\& 2)\n2. Subject has PerAF with no history of prior AF ablation therapy (Phase 3)\n3. Subject is 18 to 80 years of age\n4. Subject has presence of AF-related symptoms and is scheduled for clinically indicated standard of care AF ablation to manage PerAF (Phase 2 or 3) or long-standing PerAF (Phase 2)\n5. Subject is able to provide written informed consent\n6. Subject is able and willing to complete all study procedures\n\nExclusion Criteria:\n\n1. Any of the following within three months of enrollment:\n\n   1. Myocardial infarction (MI)\n   2. Any surgical or percutaneous cardiac procedure including coronary intervention and cardiac ablation\n   3. Confirmed thrombus on imaging\n2. Any of the following within six months of enrollment:\n\n   1. Cardiac surgery including coronary artery bypass grafting, ventriculotomy, atriotomy\n   2. Thromboembolic event (stroke)\n3. Any of the following cardiac conditions:\n\n   1. New York Heart Association (NYHA) IV\n   2. Left ventricular ejection fraction (LVEF) \\\u003C 30%\n   3. Left atrial diameter \\>55mm (anterioposterior) (Phase 3)\n   4. Carotid stenting or endarterectomy\n   5. Atrial or ventricular septal closure or left atrial appendage closure\n   6. Implanted permanent pacemaker, biventricular pacemaker, or any type of implantable cardiac defibrillator; loop recorders are permitted.\n   7. Presence of intramural thrombus, tumor (including atrial myxoma), or other abnormality that precludes vascular access, catheter introduction, or manipulation\n   8. Unstable angina\n   9. Prior mitral or tricuspid valve surgery, repair, prosthetic or mechanical valve\n   10. Moderate to severe mitral valve stenosis or other severe valvular disease\n   11. Any blood clotting or bleeding abnormalities\n4. Contraindication to systemic anticoagulation\n5. AF secondary to electrolyte imbalance, acute alcohol intoxication, or reversible or non-cardiac cause\n6. Body mass index (BMI) \\> 40 kg\u002Fm2\n7. Severe pulmonary disease, pulmonary hypertension, or any chronic respiratory condition\n8. Renal failure requiring dialysis or transplant\n9. Acute illness, active systemic infection, or sepsis\n10. Active drug or alcohol dependency\n11. Hypertrophic cardiomyopathy or cardiac amyloidosis\n12. Cor pulmonale\n13. Any contra-indication that may extend procedure time, at the discretion of the operator\n14. Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence\n15. Subject considered part of vulnerable population\n16. Life expectancy less than one year\n17. Employee of the study site or Sponsor\n18. Subjects who are currently enrolled in another study that would directly interfere with this study",{"count":547,"type":21},245,[24],"This is a global, multi-site, prospective, feasibility study.",[29],"2026-03-09",{"date":553,"type":38},"2026-03-11",{"date":555,"type":38},"2024-07-25",{"date":294,"type":21},{"name":558,"class":45},"CoreMap Inc.",3,{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":566,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":22,"phases":569,"briefSummary":570,"conditions":571,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":588},"100601901","a-study-assessing-arrhythmia-mapping-with-a-multi-electrode-mapping-catheter-100601901","NCT07116525","A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter","Clinical Evaluation of Arrhythmia Mapping With a Paddle-shaped, High-density, Multi-electrode Mapping Catheter","FEATHER","Inclusion Criteria:\n\n* Diagnosed with and candidate for clinically indicated catheter mapping and ablation procedure for the management of ventricular tachycardia, premature ventricular complex, atrial tachycardia or atrial fibrillation (participant having undergone a previous ablation procedure may be included)\n* At least one episode of the targeted arrhythmia (ventricular tachycardia, premature ventricular complex, atrial tachycardia or atrial fibrillation) must have been documented by electrocardiogram (ECG), Holter, loop recorder, telemetry, implanted device, or transtelephonic monitoring within 12 months prior to enrollment\n* Age 18 years or older\n* Signed Patient Informed Consent Form (ICF)\n* Able and willing to comply with all pre-, post-, and follow-up testing and requirements\n\nExclusion Criteria:\n\n* Study arrhythmia secondary to reversible cause, or secondary to electrolyte imbalance, thyroid disease, or non cardiac cause\n* Patients requiring left atrial procedures: left atrial size greater than (\\>) 55 millimeter (mm)\n* Left ventricular ejection fraction(LVEF) less than or equal to (\\\u003C=) 25 percentage (%) for participants with ventricular arrhythmia\n* LVEF \\\u003C= 40% for participants with atrial arrhythmia\n* Documented intracardiac thrombus as detected on imaging within 24 hours prior to insertion of the investigational catheter\n* Contraindication to anticoagulation (that is, heparin, warfarin, dabigatran)\n* History of blood clotting or bleeding abnormalities (example hypercoagulable state)\n* Myocardial infarction within the past 2 months (60 days)\n* Documented thromboembolic event (including transient ischemic attack \\[TIA\\]) within the past 12 months (365 days)\n* Uncontrolled heart failure or New York heart association (NYHA) function class IV\n* Implanted with a pacemaker or intracardiac cardiac defibrillator or appendage closure device within the past 6 weeks (42 days)\n* Patients with known untreatable allergy to contrast media\n* Active illness or active systemic infection or sepsis\n* Diagnosed atrial or ventricular myxoma, interatrial baffle or patch, tumor or other abnormality that precludes catheter introduction or manipulation\n* Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study\n* Participants that have ever undergone a percutaneous or surgical valvular cardiac procedure (that is, ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve)\n* Participants that currently have Impella or equivalent devices on the procedure date or up to 7 days prior\n* Any cardiac surgery within the past 60 days (2 months) (includes percutaneous coronary intervention \\[PCI\\])\n* Atrial septal closure within the past 6 weeks (42 days)\n* Presence of a condition that precludes vascular access\n* Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation\n* Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being\n* Concurrent enrollment in an investigational study evaluating another device or drug",{"count":262,"type":21},[24],"The purpose of this study is to assess the safety and feasibility of the investigational catheter for mapping the atrial and ventricular regions of the heart.",[572,29,33,573,574,575,576,577,578,579],"Scar-related Atrial Tachycardia","Ventricular Procedures","Ventricular Tachycardia","Ischemic Ventricular Tachycardia","Non-ischemic Ventricular Tachycardia","Cardiomyopathy","Idiopathic Ventricular Tachycardia","Premature Ventricular Contraction",{"date":581,"type":38},"2026-02-13",{"date":583,"type":38},"2025-09-15",{"date":585,"type":21},"2026-09-30",{"name":587,"class":45},"Biosense Webster, Inc.",6,{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":22,"phases":599,"briefSummary":600,"conditions":601,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":77},"100624109","pvi-alone-versus-pvi-plus-pwi-and-svci-with-pfa-100624109","NCT07405359","PVI Alone Versus PVI Plus PWI and SVCI With PFA","A Randomized Trial of Pulmonary Vein Isolation Alone Versus Pulmonary Vein Isolation Plus Posterior Wall and Superior Vena Cava Isolation With Pulsed Field Ablation for Treatment of Persistent Atrial Fibrillation","PVI-PLUS","Inclusion Criteria:\n\n* Age ≥18 years at their pre-procedure visit\n* Persistent AF, defined as at least one continuous AF episode lasting at least seven days in duration, documented by a continuous monitor or 2 ECGs\\>7 days apart or ≥3 cardioversions\n* Indicated and interested in ICM implant for monitoring post ablation\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study\n\nExclusion Criteria:\n\n* Any prior atrial endocardial or epicardial ablation procedure, other than cavotricuspid isthmus ablation or supraventricular tachycardia\n* Stroke or transient ischemic attack within the previous six months\n* Gastrointestinal bleeding within the previous three months\n* Implanted pacemaker or defibrillator\n* Longstanding persistent AF (\\> 3 years)\n* LA volume \\>80ml\u002Fm2\n* Atrial septal occlusion device\n* Current left atrial thrombus\n* Left atrial appendage occlusion or closure device \\\u003C 6 mos or with leak or prior DRT\n* Mitral or Tricuspid valve clip or mechanical replacement or clip\n* Hypertrophic cardiomyopathy\n* Contraindication to femoral vascular access\n* Congenital heart disease with residual anatomic abnormality\n* Contraindication to, or unwillingness to use, systemic anticoagulation\n* Pregnancy\n* Left ventricular ejection fraction \\\u003C30%\n* Baseline creatinine \\>2.0 mg\u002FdL\n* Predicted life expectancy less than one year\n* Refusal to receive ICM implant or allergy to ICM",{"count":598,"type":21},220,[24],"Catheter based ablation of atrial fibrillation (AF) is an established treatment modality for rhythm control of AF, with pulmonary vein isolation (PVI) being the cornerstone of this technique. While pulmonary vein triggers are the predominant arrhythmia mechanism in paroxysmal AF, development of additional atrial substrate contributes to maintenance of AF in persistent AF. This is likely to account for the lower rates of freedom from recurrent AF following ablation in patients with persistent AF. Various adjunctive empiric ablation strategies, such as left atrial posterior wall isolation (PWI), superior vena cava isolation (SVCI), linear ablation, and ablation of complex fractionated atrial electrograms have been studied to address this limitation of PVI alone.\n\nWhile observational data supports the safety and feasibility of Posterior Wall Isolation (PWI) and Superior Vena Cava Isolation (SVCI) with PFA, the efficacy of these strategies with PFA has not been demonstrated in randomized controlled trials. Whether mapping prior to ablation (i.e. detecting scar) predicts if PW and SVC sites are effective in improving ablation outcome is unknown.\n\nThis study will test the hypothesis of whether empiric addition of PW and SVC isolation with PFA to PVI improves outcome (freedom from atrial tachyarrhythmia at 1-year). The investigators therefore propose a randomized controlled trial to compare the efficacy of Pulmonary Vein Isolation (PVI) alone versus PVI + PWI + SVCI in patients with persistent AF. The investigators hypothesize that the addition of PWI and SVCI to PVI in patients with persistent AF will provide improved freedom from AFIB off anti-arrhythmic drugs, without significantly increasing rates of procedural complications. Secondary analysis includes subgroups with posterior wall scar, procedure times, freedom from AFIB on or off anti arrhythmic drugs, etc.",[29],"2026-02-04",{"date":95,"type":38},{"date":605,"type":21},"2026-02-14",{"date":607,"type":21},"2028-08-14",{"name":609,"class":206},"Edward Gerstenfeld, MD",{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":4,"eligibilityCriteria":616,"healthyVolunteers":12,"sex":17,"minAge":492,"maxAge":183,"enrollmentInfo":617,"targetDuration":4,"studyType":22,"phases":619,"briefSummary":620,"conditions":621,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":632},"100500011","effect-of-ablation-of-persistent-atrial-fibrillation-on-cognitive-function-in-individuals-with-mild-cognitive-impairment-100500011","NCT05790707","EfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment","EfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment : - The FALCON Study-","Inclusion Criteria:\n\n* Patients aged 60 to 80 years\n* Persistent atrial fibrillation\n* Patients with an indication for cardiac rhythm control.\n* Montreal Cognitive Assessment score between 18 and 25 points corresponding to mild cognitive impairment\n* Free subject, not under temporary or permanent guardianship and not subject to subordination\n* Subject understanding and accepting the constraints of the study\n* Patient covered by French national health insurance or benefiting from it through a third party\n* Subject has given written consent to the study after having received clear and complete information\n\nExclusion Criteria:\n\n* Impossibility to perform the neuropsychological evaluation (communication problems such as hearing loss or aphasia, language barrier)\n* History of clinical stroke\n* Presence of a bruit at carotid auscultation or history of severe carotid stenosis\n* History or suspicion of neurodegenerative disease (Parkinson's disease, Alzheimer's disease, Huntington's disease and amyotrophic lateral sclerosis...), bipolar disorder, schizophrenia, severe depression or amyloidosis\n* Patient with history of previous atrial fibrillation ablation\n* Patient undergoing flutter ablation or atrial tachycardia ablation (not atrial fibrillation ablation)\n* Contraindication to atrial fibrillation ablation (intracardiac thrombus, severe pulmonary hypertension, mechanical mitral valve prosthesis or contraindication to anticoagulation,…)\n* Contraindication to antiarrhythmic drugs, or to implantable cardiac monitor\n* Patient with very advanced persistent atrial fibrillation, i.e., for more than 3 years or with a left atrial diameter \\>60 mm in parasternal long axis section or a left atrial volume \\> 48ml\u002Fm2 in echocardiography\n* Subject with a life expectancy of less than 24 months at study enrolment\n* Inability to consent\n* Persons benefiting from a reinforced protection, namely minors, persons deprived of liberty by a judicial or administrative decision, adults under legal protection, and finally patients in emergency situations\n* Pregnant or breastfeeding women, women at age to procreate and not using effective contraception (hormonal\u002Fbarrier: oral, parenteral, percutaneous implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total ovariectomy)",{"count":618,"type":21},120,[24],"The goal of this clinical trial is to evaluate the effect of catheter ablation of persistent atrial fibrillation on cognitive function in patients with mild cognitive impairment. Participants will be randomized into antiarrhythmic drugs alone or atrial fibrillation ablation + antiarrhythmic drugs.",[622,29],"Mild Cognitive Impairment","2026-01-21",{"date":625,"type":38},"2026-01-23",{"date":627,"type":38},"2023-04-21",{"date":629,"type":21},"2027-07",{"name":631,"class":206},"Poitiers University Hospital",8]